113 related articles for article (PubMed ID: 11302799)
1. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects.
Creagh T; Ruckle JL; Tolbert DT; Giltner J; Eiznhamer DA; Dutta B; Flavin MT; Xu ZQ
Antimicrob Agents Chemother; 2001 May; 45(5):1379-86. PubMed ID: 11302799
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers.
Eiznhamer DA; Creagh T; Ruckle JL; Tolbert DT; Giltner J; Dutta B; Flavin MT; Jenta T; Xu ZQ
HIV Clin Trials; 2002; 3(6):435-50. PubMed ID: 12501127
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of inhibition of human immunodeficiency virus type-1 reverse transcriptase by calanolide A.
Currens MJ; Mariner JM; McMahon JB; Boyd MR
J Pharmacol Exp Ther; 1996 Nov; 279(2):652-61. PubMed ID: 8930168
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1.
Currens MJ; Gulakowski RJ; Mariner JM; Moran RA; Buckheit RW; Gustafson KR; McMahon JB; Boyd MR
J Pharmacol Exp Ther; 1996 Nov; 279(2):645-51. PubMed ID: 8930167
[TBL] [Abstract][Full Text] [Related]
5. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C).
Zembower DE; Liao S; Flavin MT; Xu ZQ; Stup TL; Buckheit RW; Khilevich A; Mar AA; Sheinkman AK
J Med Chem; 1997 Mar; 40(6):1005-17. PubMed ID: 9083491
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers.
Huang F; Koenen-Bergmann M; Macgregor TR; Ring A; Hattox S; Robinson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4300-7. PubMed ID: 18824608
[TBL] [Abstract][Full Text] [Related]
8. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical properties of related calanolide compounds with activity against human immunodeficiency virus.
Newman RA; Chen W; Madden TL
J Pharm Sci; 1998 Sep; 87(9):1077-80. PubMed ID: 9724557
[TBL] [Abstract][Full Text] [Related]
11. Quantification of (+)-calanolide A, a novel and naturally occurring anti-HIV agent, by high-performance liquid chromatography in plasma from rat, dog and human.
Xu ZQ; Norris KJ; Weinberg DS; Kardatzke J; Wertz P; Frank P; Flavin MT
J Chromatogr B Biomed Sci Appl; 2000 Jun; 742(2):267-75. PubMed ID: 10901131
[TBL] [Abstract][Full Text] [Related]
12. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum.
Kashman Y; Gustafson KR; Fuller RW; Cardellina JH; McMahon JB; Currens MJ; Buckheit RW; Hughes SH; Cragg GM; Boyd MR
J Med Chem; 1992 Jul; 35(15):2735-43. PubMed ID: 1379639
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects.
Cha YJ; Lim KS; Park MK; Schneider S; Bray B; Kang MC; Chung JY; Yoon SH; Cho JY; Yu KS
Drug Des Devel Ther; 2014; 8():1613-9. PubMed ID: 25302016
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity and resistance to (+)-calanolide A of wild-type and mutated forms of HIV-1 reverse transcriptase.
Quan Y; Motakis D; Buckheit R; Xu ZQ; Flavin MT; Parniak MA; Wainberg MA
Antivir Ther; 1999; 4(4):203-9. PubMed ID: 10723499
[TBL] [Abstract][Full Text] [Related]
15. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
16. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
17. Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor.
Hanna L
BETA; 1999 Apr; 12(2):8-9. PubMed ID: 11366704
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and tolerability of GW420867X, a nonnucleoside reverse transcriptase inhibitor, following single escalating doses in healthy male volunteers.
Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
J Clin Pharmacol; 2001 Oct; 41(10):1098-105. PubMed ID: 11583478
[TBL] [Abstract][Full Text] [Related]
19. The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A.
Auwerx J; Rodríguez-Barrios F; Ceccherini-Silberstein F; San-Félix A; Velázquez S; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
Mol Pharmacol; 2005 Sep; 68(3):652-9. PubMed ID: 15961674
[TBL] [Abstract][Full Text] [Related]
20. Calanolide at UTMB.
Res Initiat Treat Action; 1999 Jan; 5(1):20. PubMed ID: 11366230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
